Ann: Appendix 4C - June 2019 Quarterly Report, page-2

Pros:
- Richard met with tier 1 diagnostics groups in the US for the US roll-out
- News due in 'the coming weeks' around Mexico and Spain roll out
- Janseen collaboration going as planned, reiterating the potential use of PD every time Gliflozin is prescribed.
- FY19 receipts were $1.7M, more than double PY
- Upcoming $1.1m in R&D rebate to further strength cash position which is currently at $1.5M

Cons:
- Endometrosis POC delayed due to mass spectrometry machine failure
- Giardia POC now in a second POC stage? didnt' know 2 POC's were required..
- Dominican Republic royalties either not included or was minuscule
- Quarterly receipts only $245k

Overall pretty good just a dam shame we are taking so long to commercialize PromarkerD considering it was ready nearly 2 years ago.
One can dream but imagine what this means for us if we partner with a tier1 diagnostics group in the U.S and the Jannsen collaboration goes according to plan? Good luck guys and look forward to every one else thoughts on the quarterly.